帕博利珠单抗治疗晚期非小细胞肺癌患者的五年总生存率:I期KEYNOTE-001研究结果
KEYNOTE-001研究报道帕博利珠单抗单药治疗晚期PD-L1表达非小细胞肺癌的5年结局,中位随访60.6个月,初治患者中位OS 22.3个月、5年OS率23.2%,经治患者分别为10.5个月和15.5%,长期安全性可耐受。
要点
- 初治患者中位OS 22.3个月,5年OS率23.2%;经治患者分别为10.5个月和15.5%。
- PD-L1 TPS≥50%者5年OS率初治29.6%、经治25.0%。
- 3年后仅新增3例治疗相关3级不良事件,无迟发性4级或5级治疗相关不良事件。
核心结论
- 帕博利珠单抗单药在初治或经治晚期NSCLC中提供持久的抗肿瘤活性和较高的5年OS率。
- PD-L1肿瘤比例评分≥50%的患者5年OS率超过25%。
- 帕博利珠单抗长期安全性可耐受,迟发性或新发毒性证据很少。
研究设计与样本
- Ib期KEYNOTE-001研究,纳入确诊局部晚期/转移性NSCLC且提供同期肿瘤样本经22C3抗体免疫组化评估PD-L1的患者。
- 患者接受静脉帕博利珠单抗2 mg/kg每3周或10 mg/kg每2或3周。
- 共纳入101例初治和449例经治患者,中位随访60.6个月(范围51.8至77.9个月)。
- 主要疗效终点为客观缓解率,OS和缓解持续时间为次要终点,研究者按免疫相关缓解标准评估缓解。
主要发现
- 数据截止2018年11月5日,450例患者(82%)死亡。
- 初治患者中位OS 22.3个月(95% CI 17.1至32.3个月),经治患者中位OS 10.5个月(95% CI 8.6至13.2个月)。
- 估计5年OS率初治患者23.2%,经治患者15.5%。
- PD-L1肿瘤比例评分≥50%者,5年OS率初治患者29.6%,经治患者25.0%。
- 与3年分析相比,仅新增3例新发治疗相关3级不良事件(高血压、葡萄糖不耐受和过敏反应,均缓解),无迟发性4级或5级治疗相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)-expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for patients with NSCLC treated with pembrolizumab monotherapy. PATIENTS AND METHODS: Eligible patients had confirmed locally advanced/metastatic NSCLC and provided a contemporaneous tumor sample for PD-L1 evaluation by immunohistochemistry using the 22C3 antibody. Patients received intravenous pembrolizumab 2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks. Investigators assessed response per immune-related response criteria. The primary efficacy end point was objective response rate. Overall survival (OS) and duration of response were secondary end points. RESULTS: We enrolled 101 treatment-naive and 449 previously treated patients. Median follow-up was 60.6 months (range, 51.8 to 77.9 months). At data cutoff-November 5, 2018-450 patients (82%) had died. Median OS was 22.3 months (95% CI, 17.1 to 32.3 months) in treatment-naive patients and 10.5 months (95% CI, 8.6 to 13.2 months) in previously treated patients. Estimated 5-year OS was 23.2% for treatment-naive patients and 15.5% for previously treated patients. In patients with a PD-L1 tumor proportion score of 50% or greater, 5-year OS was 29.6% and 25.0% in treatment-naive and previously treated patients, respectively. Compared with analysis at 3 years, only three new-onset treatment-related grade 3 adverse events occurred (hypertension, glucose intolerance, and hypersensitivity reaction, all resolved). No late-onset grade 4 or 5 treatment-related adverse events occurred. CONCLUSION: Pembrolizumab monotherapy provided durable antitumor activity and high 5-year OS rates in patients with treatment-naive or previously treated advanced NSCLC. Of note, the 5-year OS rate exceeded 25% among patients with a PD-L1 tumor proportion score of 50% or greater. Pembrolizumab had a tolerable long-term safety profile with little evidence of late-onset or new toxicity.
引用
- Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019. PMID: 31154919. doi:10.1200/JCO.19.00934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。